Immunosuppressive exosomes, particularly those derived from dendritic cells, blood plasma, or serum, show potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA.
Do immunosuppressive exosomes provide therapeutic efficacy in the treatment of rheumatoid arthritis?
Immunosuppressive exosomes represent a promising novel therapeutic approach for rheumatoid arthritis based on preclinical models.
Rheumatoid arthritis (RA) is a chronic autoimmune disease and one of the leading causes of disability in the USA. Although certain biological therapies, including protein and antibodies targeting inflammatory factors such as the tumor necrosis factor, are effective in reducing symptoms of RA, these treatments do not reverse disease. Also, although novel gene therapy approaches have shown promise in preclinical and clinical studies to treat RA, it is still unclear whether gene therapy can be readily and safely applied to treat the large number of RA patients. Recently, nanosized, endocytic-derived membrane vesicles "exosomes" were demonstrated to function in cell-to-cell communication and to possess potent immunoregulatory properties. In particular, immunosuppressive DC-derived exosomes and blood plasma- or serum-derived exosomes have shown potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA. This paper discusses the current knowledge on the production, efficacy, mechanism of action, and potential therapeutic use of immunosuppressive exosomes for arthritis therapy.
Yang et al. (Sun,) conducted a review in Rheumatoid arthritis. Immunosuppressive exosomes was evaluated. Immunosuppressive exosomes, particularly those derived from dendritic cells, blood plasma, or serum, show potent therapeutic effects in animal models of inflammatory and autoimmune disease including RA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: